<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554966</url>
  </required_header>
  <id_info>
    <org_study_id>M19-966</org_study_id>
    <nct_id>NCT04554966</nct_id>
  </id_info>
  <brief_title>Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)</brief_title>
  <official_title>A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ABBV-382 in Persons Living With HIV-1 (PLWH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency&#xD;
      Syndrome (AIDS). HIV infection is considered to be a chronic disease requiring lifelong&#xD;
      therapy. This study will evaluate how safe ABBV-382 is and how it is absorbed, distributed&#xD;
      and eliminated from the body in adult participants with HIV-1 infection.&#xD;
&#xD;
      ABBV-382 is an investigational drug being developed for the treatment of HIV-1 infection.&#xD;
      This study takes place in 2 parts. In Part A, participants with HIV-1 and no history of&#xD;
      combination antiretroviral therapy (cART) or who are off cART for more than 3 months will be&#xD;
      enrolled to receive ABBV-382. In Part B, participants with no virus in their blood and on&#xD;
      maintenance cART will be enrolled into one of the intravenous (IV) or subcutaneous (SC)&#xD;
      groups. In the IV groups, participants will receive either placebo or ABBV-382 whereas&#xD;
      participants in the SC group will receive ABBV-382. There is 1 in 3 chance that participants&#xD;
      will receive placebo (no drug) in Part B IV groups. The IV group in Part B is double-blinded&#xD;
      which means neither the study doctors nor the participants will know who will be given study&#xD;
      drug or placebo. Around 52 adult participants with HIV-1 infection will be enrolled at&#xD;
      approximately 21 sites across the United States, including Puerto Rico.&#xD;
&#xD;
      Participants in Part A will receive an intravenous (IV) dose of ABBV-382 on Day 1.&#xD;
      Participants in Part B will receive an IV or SC dose of ABBV-382 or placebo on Days 1, 29 and&#xD;
      57.&#xD;
&#xD;
      There may be a higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will attend regular visits during the study at a hospital or&#xD;
      clinic. The effect of the treatment will be checked by medical assessments, blood tests, and&#xD;
      presence of side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Anticipated">September 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Study Drug-Related Grade 3 or Higher Adverse Events (AEs)</measure>
    <time_frame>Up to Day 255</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either &quot;Reasonable Possibility&quot; or &quot;No Reasonable Possibility&quot; and will assess the severity of each adverse event from Grade 1 (mild) to Grade 4 (potentially life-threatening).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of ABBV-382 (Part A and Part B)</measure>
    <time_frame>Up to Day 225</time_frame>
    <description>Maximum observed serum concentration (Cmax) of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ABBV-382 (Part A and Part B)</measure>
    <time_frame>Up to Day 225</time_frame>
    <description>Time to Cmax (Tmax) of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-382 (Part A)</measure>
    <time_frame>Up to Day 112</time_frame>
    <description>Area under the serum concentration-time curve (AUC) from time 0 to the time of last measurable concentration (AUCt) of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-382 (Part A)</measure>
    <time_frame>Up to Day 112</time_frame>
    <description>AUC from time 0 to infinite time (AUCinf) of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Rate Constant (β) of ABBV-382 (Part A)</measure>
    <time_frame>Up to Day 112</time_frame>
    <description>Terminal phase elimination rate constant of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-Life (t1/2) of ABBV-382 (Part A)</measure>
    <time_frame>Up to Day 112</time_frame>
    <description>Terminal phase elimination half-life of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Concentration at the End of the 4-Week Dosing Interval (Ctrough) of ABBV-382 (Part B)</measure>
    <time_frame>Up to Day 225</time_frame>
    <description>Observed concentration at the end of the 4-week dosing interval (Ctrough) of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC During the 4-Week Dosing Interval (AUCtau) of ABBV-382 (Part B)</measure>
    <time_frame>Up to Day 225</time_frame>
    <description>AUC during the 4-week dosing interval (AUCtau) of ABBV-382.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-Life (t1/2) of ABBV-382 (Part B)</measure>
    <time_frame>Day 57 to Day 225</time_frame>
    <description>Terminal phase elimination half-life (t1/2) of ABBV-382 will be estimated after the third dose only.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>Part A: ABBV-382 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: ABBV-382 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Intravenous Cohort: ABBV-382 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Intravenous Cohort: ABBV-382 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Subcutaneous Cohort: ABBV-382</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-382</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Part A: ABBV-382 Dose A</arm_group_label>
    <arm_group_label>Part A: ABBV-382 Dose B</arm_group_label>
    <arm_group_label>Part B: Intravenous Cohort: ABBV-382 Dose A</arm_group_label>
    <arm_group_label>Part B: Intravenous Cohort: ABBV-382 Dose B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-382</intervention_name>
    <description>Subcutaneous (SC) injection</description>
    <arm_group_label>Part B: Subcutaneous Cohort: ABBV-382</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABBV-382</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A</arm_group_label>
    <arm_group_label>Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) is &gt;= 18.0 to &lt;= 35.0 kg/m^2 after rounding to the tenths&#xD;
             decimal.&#xD;
&#xD;
          -  Must agree to use effective barrier protection during sexual activity for protection&#xD;
             against Human Immunodeficiency Virus (HIV)-1 transmission through the last study&#xD;
             visit.&#xD;
&#xD;
          -  Female participants of childbearing potential must give consent to abide by&#xD;
             contraception requirements.&#xD;
&#xD;
          -  CD4+ count of &gt;= 350 cells/μL at screening and at least once during the 48 weeks prior&#xD;
             to screening.&#xD;
&#xD;
          -  Negative screen for drugs of abuse and alcohol at screening. Participants with a&#xD;
             positive marijuana screen may be included after evaluation by the investigator that&#xD;
             the use would not interfere with adherence to study requirements, and that usage is&#xD;
             not on a regular or chronic basis.&#xD;
&#xD;
          -  Laboratory values must meet the acceptable criteria.&#xD;
&#xD;
        Part A participants must also have:&#xD;
&#xD;
          -  Positive test result for anti-HIV antibody at screening.&#xD;
&#xD;
          -  Plasma HIV-1 ribose nucleic acid (RNA) between 1,000 - 200,000 copies/mL at screening.&#xD;
&#xD;
          -  Must be naive to combination antiretroviral therapy (cART) or have been off of cART&#xD;
             for &gt; 12 weeks or 5 half-lives of the drug (whichever is longer) prior to screening&#xD;
             with documentation of at least one plasma HIV-1 RNA measurement greater than or equal&#xD;
             to the lower limit of quantification (LLOQ) during the off cART period.&#xD;
&#xD;
          -  Willing to hold on initiation of cART throughout the screening period and until 4&#xD;
             weeks after dosing.&#xD;
&#xD;
        Part B participants must also have:&#xD;
&#xD;
          -  Positive test result for anti-HIV antibody at screening.&#xD;
&#xD;
          -  Must have plasma HIV-1 RNA below the lower limit of quantification at screening and at&#xD;
             least 24 weeks prior to screening. A single unconfirmed &quot;blip&quot; is allowed if preceded&#xD;
             and followed by values below the lower limit of quantification.&#xD;
&#xD;
          -  Must be HIV-1 infected on cART for at least 48 weeks prior to screening and on current&#xD;
             cART regimen for at least 12 weeks prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participants who are pregnant, breastfeeding, or considering becoming pregnant&#xD;
             during the study.&#xD;
&#xD;
          -  History or ongoing diagnosis of acquired immune deficiency syndrome (AIDS)-defining&#xD;
             illness.&#xD;
&#xD;
          -  History of or active immunodeficiency (other than HIV).&#xD;
&#xD;
          -  Active autoimmune disease or history of autoimmune disease that has required systemic&#xD;
             treatment.&#xD;
&#xD;
          -  Clinically significant medical disorders (other than HIV-1 infection) that might&#xD;
             expose the participant to undue risk of harm, confound study outcomes, or prevent the&#xD;
             participant from completing the study.&#xD;
&#xD;
          -  Active or suspected malignancy or history of malignancy (other than basal cell skin&#xD;
             cancer or cervical carcinoma in situ) in the past 5 years.&#xD;
&#xD;
          -  History or evidence of active tuberculosis (TB) disease or untreated latent TB&#xD;
             infection at screening.&#xD;
&#xD;
          -  No history of positive TB skin test or interferon gamma release assay (IGRA) or at&#xD;
             screening which is considered clinically significant by the investigator. Participant&#xD;
             with a history of a positive TB skin test or IGRA or at screening must have&#xD;
             documentation of completion of a Centers for Disease Control and Prevention (CDC)&#xD;
             recommended treatment course for latent TB. Any participant with suspicion for or&#xD;
             diagnosis of active TB is excluded.&#xD;
&#xD;
          -  Known psychiatric or substance abuse disorders that would interfere with adherence to&#xD;
             study requirements.&#xD;
&#xD;
          -  Currently enrolled in another interventional clinical study.&#xD;
&#xD;
          -  Received immunomodulatory or immunosuppressive (including intravenous [IV]/oral [PO]&#xD;
             steroids at any dose, but excluding steroids that are inhaled or topical) therapy&#xD;
             within 24 weeks prior to the first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Franco Felizarta, Md /Id# 223815</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group /ID# 224125</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research /ID# 223347</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-3037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates /ID# 223493</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037-3201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research /ID# 223500</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center /ID# 223498</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute /ID# 223460</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407-3100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC /ID# 225526</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinite Clinical Trials - Morrow /ID# 225455</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260-2342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics /ID# 224267</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center /ID# 223381</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072-3046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital Manhasset /ID# 223343</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital /ID# 224871</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research /ID# 223378</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705-3326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Health North Texas - Oak Cliff Health Center /ID# 223237</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208-4599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North TX Infectious Diseases /ID# 223236</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, Inc /ID# 223383</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Shalit, M.D. /ID# 224252</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-3595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Deaconess Hospital /ID# 225538</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204-2803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation /ID# 224231</name>
      <address>
        <city>Ponce</city>
        <zip>00716-0377</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Puerto Rico /ID# 223923</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV-1</keyword>
  <keyword>ABBV-382</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

